RxDoctor Payments Data

Amy Hudson

Nurse Practitioner · Houston, TXNPI 1548429483

Payments from drug & device makers

$6,187in general payments, 2019–2025

Across 179 payments — averaging $34.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Impulse Dynamics (USA) Inc.$959
  • Merck$447
  • Johnson & Johnson$355
  • Novartis$347
  • AstraZeneca$249
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$6,11699%
  • Education$711%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,187 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$12,102
Medicare patients
49
Services billed
128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan67$76,382
EliquisApixaban66$71,164
XareltoRivaroxaban44$48,780
FarxigaDapagliflozin Propanediol49$36,762
OzempicSemaglutide12$14,111
Ranolazine ErRanolazine40$6,781
Nifedipine ErNifedipine72$2,607
Metoprolol Succinate102$1,613
Amiodarone Hcl42$1,496
Midodrine Hcl12$1,348
Atorvastatin Calcium101$1,069
Olmesartan Medoxomil15$1,003
Rosuvastatin Calcium47$983
Losartan Potassium113$831
Nitroglycerin72$784

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$347$76,38267 claims
Johnson & JohnsonXarelto$355$48,78044 claims
AstraZenecaFarxiga$249$36,76249 claims
Novo NordiskOzempic$69$14,11112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →